Annual report pursuant to Section 13 and 15(d)

Equity Investment (Details Narrative)

v3.22.1
Equity Investment (Details Narrative) - USD ($)
12 Months Ended
Mar. 12, 2021
Dec. 31, 2021
Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]      
Aggregrate investment   $ 6,000,000  
Equity investment   5,000,000  
Convertable note investment   1,000,000  
Iliad [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Aggregrate investment   6,000,000  
Equity investment   5,000,000  
Equity investment net loss   $ 999,000 $ 787,000
Iliad [Member] | Class C Units [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Ownership percentage not fully diluted   9.50%  
Ownership percentage fully diluted   7.20%  
I Liad Biotechnologies L L C [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Additional convertable note investment $ 1,000,000    
Maximum convertible debt offering $ 23,500,000    
Interest rate 6.00%    
Notes conversion, description The Notes are required to be converted into a Qualified Financing (minimum financing of $15 million) at the lesser of (i) 80% of the price paid per unit in such offering or (ii) a price based on an enterprise value of $176,000,000. In addition, the Notes shall convert in the event of a merger at the lower of an enterprise value of $176,000,000 or the stated valuation of ILiAD in the merger transaction. In the event of a change-in-control, noteholders will also have the option to have the Notes repaid except in a Qualified Financing or a stock-for-stock merger.